# A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

> **NCT03836001** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 28 (actual)

## Conditions studied

- Epidermolysis Bullosa

## Interventions

- **DRUG:** Serlopitant Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03836001
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-18
- **Primary completion:** 2021-12-06
- **Final completion:** 2022-06-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836001, "A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03836001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*